A patent infringement suit filed by Merck & Co. Inc. against Teva Parenteral Medicines, Inc. relating to Cancidas is ongoing, Merck disclosed in its August 8, 2011, Form 10-Q filing…
A patent infringement suit filed by Merck & Co. Inc. against Apotex Corp. relating to Nasonex is pending, Merck disclosed in its August 8, 2011, Form 10-Q filing with the…
A patent infringement suit filed by Merck & Co. Inc. against Hamni USA, Inc. relating to Nexium is pending, Merck disclosed in its August 8, 2011, Form 10-Q filing with…
A patent infringement suit filed by Merck & Co. Inc. against Lupin Ltd. relating to Nexium is ongoing with no trial dates presently scheduled, Merck disclosed in its August 8,…
A patent infringement suit filed by Merck & Co. Inc. against Sandoz Inc. relating to AzaSite is pending, Merck disclosed in its August 8, 2011, Form 10-Q filing with the…
A patent infringement suit filed by Merck & Co. Inc. against Teva Parenteral Medicines, Inc. relating to Integrilin is pending, Merck disclosed in its August 8, 2011, Form 10-Q filing…
Merck & Co. Inc. continues to cooperate with the Federal Trade Commission after it received a Civil Investigative Demand regarding a patent settlement agreement it entered with Ranbaxy Laboratories Ltd.,…
Merck & Co. Inc.’s patent infringement suit against Mylan Pharmaceuticals, Inc. relating to Zetia remains pending.
In May 2010, Schering Corp. received notice from Mylan Pharmaceuticals, Inc. that it filed an…
A decision in Merck & Co. Inc.’s lawsuit seeking a prohibition order against the approval of Teva Pharmaceuticals, Inc application to sell the Company generic ezetimibe prior to the September…
Merck & Co. Inc.’s patent infringement suit against Teva Pharmaceuticals, Inc. relating to ezetimibe/simvastatin is pending.
In February 2010, Schering Corp. received notice from Teva that it filed an ANDA for…